PD-1/PD-L1 抑制剂治疗肺癌的影像学评价。
Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors.
机构信息
Department of Radiology, Xiangya Hospital, Central South University, Changsha, China.
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
出版信息
Br J Radiol. 2021 Nov 1;94(1127):20210228. doi: 10.1259/bjr.20210228. Epub 2021 Sep 19.
Abstract
Immunotherapy (PD-1/PD-L1 inhibitors) has attracted attention for lung cancer treatment and recasted the administration of immunotherapeutics to patients who have advanced/metastatic diseases. Whether in combination or as monotherapy, these medications have become common therapies for certain patients with lung cancer. Moreover, their usage is expected to expand widely in the future. This review aims to discuss the imaging evaluation of lung cancer response to PD-1/PD-L1 therapy with focus on new radiological criteria for immunotherapy response. Abnormal radiological responses (pseudoprogression, dissociative responses, and hyperprogression) and immune-related adverse events are also described.
摘要
免疫疗法（PD-1/PD-L1 抑制剂）在肺癌治疗中引起了关注，并重新调整了免疫治疗药物在晚期/转移性疾病患者中的应用。这些药物无论是联合使用还是作为单一疗法，都已成为某些肺癌患者的常见治疗方法。此外，预计它们的使用在未来将广泛扩展。本文旨在讨论 PD-1/PD-L1 治疗肺癌反应的影像学评估，重点介绍免疫治疗反应的新影像学标准。还描述了异常的影像学反应（假性进展、分离反应和超进展）和免疫相关不良事件。
相似文献
1
Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors.PD-1/PD-L1 抑制剂治疗肺癌的影像学评价。
Br J Radiol. 2021 Nov 1;94(1127):20210228. doi: 10.1259/bjr.20210228. Epub 2021 Sep 19.
2
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.循环调节性 T 细胞可预测接受 PD-1/PD-L1 抑制剂治疗的肺癌患者的疗效和非典型反应。
Cancer Immunol Immunother. 2022 Mar;71(3):579-588. doi: 10.1007/s00262-021-03018-y. Epub 2021 Jul 18.
3
Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.PD-1/PD-L1 抑制剂联合放疗治疗非小细胞肺癌患者的安全性和疗效：系统评价和荟萃分析。
Cancer Med. 2021 Feb;10(4):1222-1239. doi: 10.1002/cam4.3718. Epub 2021 Jan 19.
4
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
5
Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.抗 PD-1 或 PD-L1 抑制剂治疗期间转移性 NSCLC 的缓解模式：RECIST 1.1 与 iRECIST 标准的比较。
Thorac Cancer. 2020 Apr;11(4):1068-1075. doi: 10.1111/1759-7714.13367. Epub 2020 Mar 4.
6
Immunotherapy in Advanced Lung Cancer.晚期肺癌的免疫治疗。
Oncology (Williston Park). 2020 Jul 15;34(7):272-279.
7
Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.胸膜或心包转移：影响肺癌患者接受 PD-1/PD-L1 抑制剂治疗疗效和不良事件的重要因素。
Thorac Cancer. 2018 Nov;9(11):1500-1508. doi: 10.1111/1759-7714.12877. Epub 2018 Sep 25.
8
Immunotherapy in lung cancer.肺癌的免疫治疗。
J Surg Oncol. 2021 Mar;123(3):718-729. doi: 10.1002/jso.26347.
9
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.晚期非小细胞肺癌患者中抗 PD-1 和抗 PD-L1 抗体免疫检查点抑制剂再挑战时的给药切换：病例系列和文献复习。
Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.
10
The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.程序性死亡受体-1与程序性死亡配体1疗法在晚期非小细胞肺癌中的相对和绝对获益：一项系统评价与荟萃分析。
Int Immunopharmacol. 2020 Oct;87:106852. doi: 10.1016/j.intimp.2020.106852. Epub 2020 Aug 3.
引用本文的文献
1
Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).免疫检查点抑制剂治疗相关肺炎：如何、何时以及为何进行诊断与管理（综述）
Exp Ther Med. 2024 Jul 30;28(4):381. doi: 10.3892/etm.2024.12670. eCollection 2024 Oct.
2
Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients.提高安全性和治疗效果：PD-1抑制剂与重组人内皮抑素联合用于晚期非小细胞肺癌患者
Am J Transl Res. 2024 Jun 15;16(6):2483-2491. doi: 10.62347/PNQT4160. eCollection 2024.
3
PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events.PD-1/PD-L1抑制剂治疗及其对非小细胞肺癌临床影像的影响：免疫相关不良事件的系统评价和荟萃分析
Front Oncol. 2023 Sep 29;13:1191681. doi: 10.3389/fonc.2023.1191681. eCollection 2023.
4
Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study.澳大利亚新南威尔士州的出生地与非小细胞肺癌发病、治疗和结局：基于人群的关联研究。
BMC Pulm Med. 2022 Sep 27;22(1):366. doi: 10.1186/s12890-022-02163-z.
本文引用的文献
1
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.用于预测和评估癌症免疫治疗反应的基于成像的生物标志物
Radiol Imaging Cancer. 2019 Nov 29;1(2):e190031. doi: 10.1148/rycan.2019190031. eCollection 2019 Nov.
2
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy.精准癌症治疗时代的药物相关性肺炎
JCO Precis Oncol. 2017 May 26;1. doi: 10.1200/PO.17.00026. eCollection 2017.
3
The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer.影像学研究在评估肺癌免疫治疗反应中的重要性。
Arch Bronconeumol (Engl Ed). 2020 Jun;56(6):380-389. doi: 10.1016/j.arbres.2019.10.023. Epub 2019 Dec 30.
4
Emerging therapies for small cell lung cancer.小细胞肺癌的新兴疗法。
J Hematol Oncol. 2019 May 2;12(1):47. doi: 10.1186/s13045-019-0736-3.
5
Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion.免疫治疗相关肺部毒性的管理：病例讨论
Oncologist. 2019 Jun;24(6):730-734. doi: 10.1634/theoncologist.2018-0241. Epub 2019 Mar 21.
6
Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.接受 PD-1 抑制剂治疗的转移性肺癌患者腹部免疫相关不良事件的频率和影像学特征。
Abdom Radiol (NY). 2019 May;44(5):1917-1927. doi: 10.1007/s00261-019-01935-2.
7
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?非小细胞肺癌免疫治疗中的假性进展：沧海一粟？
J Thorac Oncol. 2019 Mar;14(3):328-331. doi: 10.1016/j.jtho.2018.12.011.
8
Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: A new response pattern to be recognized by the radiologist.
Diagn Interv Imaging. 2019 May;100(5):313-315. doi: 10.1016/j.diii.2018.12.004. Epub 2019 Feb 8.
9
The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.传统 RECIST 时代的终结——新型疗法需要新型影像学方法。
Nat Rev Clin Oncol. 2019 Jul;16(7):442-458. doi: 10.1038/s41571-019-0169-5.
10
Novel patterns of response under immunotherapy.免疫治疗下的新型应答模式。
Ann Oncol. 2019 Mar 1;30(3):385-396. doi: 10.1093/annonc/mdz003.
Zotero 插件